Stocks and InvestingStocks and Investing
Tue, October 31, 2023
Mon, October 30, 2023
Fri, October 27, 2023

Michael Ulz Maintained (BPMC) at Hold with Increased Target to $63 on, Oct 27th, 2023


Published on 2024-10-28 07:08:36 - WOPRAI, Michael Ulz
  Print publication without navigation


Michael Ulz of Morgan Stanley, Maintained "Blueprint Medicines Corporation" (BPMC) at Hold with Increased Target from $59 to $63 on, Oct 27th, 2023.

Michael has made no other calls on BPMC in the last 4 months.



There are 4 other peers that have a rating on BPMC. Out of the 4 peers that are also analyzing BPMC, 0 agree with Michael's Rating of Hold.



These are the ratings of the 4 analyists that currently disagree with Michael


  • Reni Benjamin of "JMP Securities" Reiterated at Buy and Held Target at $114 on, Monday, August 7th, 2023
  • Terence Flynn of "Goldman Sachs" Maintained at Strong Buy with Decreased Target to $83 on, Thursday, August 3rd, 2023
  • Andrew Fein of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $85 on, Thursday, August 3rd, 2023
  • Derek Archila of "Wells Fargo" Upgraded from Hold to Buy and Increased Target to $83 on, Monday, July 31st, 2023